Anaplastic Malignant Neoplasm — Trials

Anaplastic Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

2,019 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 546
Recruiting: 290
Ph III recruiting: 18
Growth YoY: +34.5%
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: 33.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (324)

clinicaltrialsPublishedShowing 1–19 of 19 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06325683	Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma	suspended	Phase 2	184	National Cancer Institute (NCI)NIH	1	Sep 29, 2026	clinicaltrials
NCT07708961	Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma	suspended	Phase 2	60	Mayo ClinicOTHER	1	Sep 23, 2026	clinicaltrials